• 作者：Elisa Cuadrado-Godia ; ^{ecuadrado@imas.imim.es} ; Elvira Munteis ; José ; Enrique Martí ; nez-Rodrí ; guez ; Claustre Pont-Sunyer ; Grà ; cia Cucurella ; Jaume Roquer
• 关键词：Esclerosis multiple ; Interfer&oacute ; n beta ; Colesterol ; Triglic&eacute ; ridos
• 刊名：Medicina Cl铆nica
• 出版年：2009
• 期刊代码：pca254_00257753
• 类别：med
• 出版时间：28 February 2009
• 卷：132
• 期：7
• 页码：259-261
• 文件大小：127 K

class="h4">Background and objective

Treatment with beta interferon (IFN尾) might alter the lipid profile. Plasmatic levels of total cholesterol and low density lipoprotein-cholesterol have been associated with the number of plaques in magnetic resonance of patients with demyelinating syndromes.

class="h4">Patients and method

Retrospective analysis of total cholesterol and triglyceride levels during the first year of treatment with IFN尾 in multiple sclerosis patients and association between lipid levels and disease activity, compared to patients using glatiramer acetate (GA).

class="h4">Results

84 patients under IFN尾 and 23 GA patients were studied. Mean total cholesterol plasmatic levels lowered during the first year, whereas triglyceride levels rose since the first 6 months. These changes were more intense in the IFN尾_1a intramuscular group. No changes were observed in the GA group. Lipid changes were not associated with disease activity.

class="h4">Conclusions

In multiple sclerosis patients, triglyceride levels rise whereas total cholesterol levels decrease during the first year of treatment with IFN尾. These changes do not seem to be related with disease activity.